Articles From: Synergy Pharmaceuticals Reports Third Quarter 2014 Financial Results to Synopsys Surpasses Milestone of 100 VC Apps on the Verdi Debug Solution


Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), today reported its financial results and business update for the three and nine months ended September 30, 2014.
Sign-up for Synergy Pharmaceuticals Reports Third Quarter 2014 Financial Results investment picks
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), today announced its Chairman and Chief Executive Officer, Dr.
Sign-up for Synergy Pharmaceuticals to Present at Credit Suisse 2014 Healthcare Conference investment picks
IBM Among Top 3 Cloud Providers ARMONK, N.Y. , Nov.
Sign-up for Synergy Research Ranks IBM as the #1 Hybrid Cloud Provider for the Enterprise investment picks
The Dual Wavelength PicoWay® Laser will be launched immediately in the US and featured at The American Society of Dermatologic Surgery Meeting, San Diego, November 6-9 WAYLAND, Mass.
Sign-up for Syneron Candela Announces FDA Clearance of PicoWay Picosecond Laser for Tattoo Removal investment picks
2014/11/17
FDA cleared U-Sculpt compact transducer is optimized for treatment of fat pockets of any shape and size.
Sign-up for Syneron Candela Expands Capabilities of UltraShape Non-Invasive Fat Destruction Platform, Receives FDA Clearance for the New U-Sculpt Transducer and Enhanced Ultrasound Power investment picks
FDA Clearance for NS3000, a 30 Watt Holmium Laser for the Urology Market ROSEVILLE, Calif.
Sign-up for Syneron Candela Signs Agreement with American Medical Systems to Supply Holmium Laser for Urology investment picks
YOKNEAM, Israel , Dec.
Sign-up for Syneron Medical Announces $20 Million Share Repurchase Program investment picks
Total revenue in the range of $72 to $74 million, up 20% to 24% y/y (pro-forma excluding Syneron Beauty), including approximately 50% product revenue growth in North America Strong UltraShape full commercial launch in U.S. with more than 50 systems sold Successful global launch of PicoWay with approximately $2.5 million in sales from mid-November through the end of the year YOKNEAM, Israel , Jan.
Sign-up for Syneron Medical Announces Preliminary Fourth Quarter 2014 Revenue investment picks
Ilan Nacasch, formerly of SodaStream and Procter & Gamble, to lead global marketing and branding for all Syneron-Candela products YOKNEAM, Israel , Jan.
Sign-up for Syneron Medical Strengthens Management Team with Addition of Chief Brand Officer investment picks
YOKNEAM, Israel , Nov.
Sign-up for Syneron Medical to Participate in Three Investor Conferences in November investment picks
YOKNEAM, Israel , Oct.
Sign-up for Syneron Medical to Report Third Quarter 2014 Financial Results on November 12, 2014 investment picks
Total revenue of $60.3 million; North America revenue grew 16.3% y/y Generated $4.9 million in cash from operations Received FDA clearance for PicoWay; immediate U.S. launch in November 2014 UltraShape U.S. full commercial launch underway YOKNEAM, Israel , Nov.
Sign-up for Syneron Reports Third Quarter 2014 Results investment picks
2014/12/22
BASEL, Switzerland , December 22, 2014 /PRNewswire/ -- Import approval granted for food and feed use Agrisure Viptera ® offers unrivalled control of above-ground pests Key component of Syngenta's integrated insect control solutions Syngenta today announced that it has received the safety certificate for its Agrisure Viptera ® trait (event MIR162) from China's regulatory authorities, formally granting import approval.
Sign-up for Syngenta Receives Chinese Import Approval for Agrisure Viptera® Corn Trait investment picks
SYNNEX Corporation (NYSE: SNX), a leading business process services company, today announced financial results for the fiscal fourth quarter and year ended November 30, 2014.
Sign-up for SYNNEX Corporation Reports Record Revenue and Income for Fiscal 2014 Fourth Quarter and Full Year investment picks
SYNNEX Corporation (NYSE:SNX), a leading business process services company, will announce fiscal fourth quarter and annual results for the period ended November 30, 2014 after market close on Monday, January 12, 2015.
Sign-up for SYNNEX Corporation to Announce Fiscal Fourth Quarter and Annual Results on January 12, 2015 investment picks
SYNNEX Corporation (NYSE:SNX), a leading business process services company, announced today its plans to participate in the 17 th Annual Needham Growth Conference on January 15, 2015 at the New York Palace Hotel in New York City.
Sign-up for SYNNEX Corporation to Participate in the 17th Annual Needham Growth Conference investment picks
SYNNEX Corporation (NYSE:SNX), a leading business process services company, announced today its plans to participate in the Raymond James S4 (Systems, Semiconductors, Software & Supply Chain) Conference on December 9, 2014 at the New York Marriott East Side.
Sign-up for SYNNEX Corporation to Participate in the Raymond James Systems, Semiconductors, Software & Supply Chain Conference investment picks
Synopsys Synplify Pro Synthesis Tool Delivers Superior Quality of Results for Users of Gowin Semiconductor FPGAs MOUNTAIN VIEW, Calif.
Sign-up for Synopsys and Gowin Semiconductor Ink Multi-Year OEM Agreement for FPGA Design Software investment picks
Enables Delivery of Accurate Sentaurus TCAD Models for Nanowire, FinFET and Tunnel-FET Transistors MOUNTAIN VIEW, Calif.
Sign-up for Synopsys and Imec Expand TCAD Collaboration to 5 nm and Beyond investment picks
Silicon-Proven, Reprogrammable NVM IP Delivers Smallest Area for Calibration and Trimming Applications MOUNTAIN VIEW, Calif.
Sign-up for Synopsys Announces Availability of DesignWare Non-Volatile Memory IP for TowerJazz 180-nm Process Technology investment picks
MOUNTAIN VIEW, Calif.
Sign-up for Synopsys Announces Earnings Release Date for Fourth Quarter and Fiscal Year 2014 investment picks
MOUNTAIN VIEW, Calif.
Sign-up for Synopsys Appoints Janice Chaffin to Board of Directors investment picks
MOUNTAIN VIEW, Calif.
Sign-up for Synopsys Co-CEO Aart de Geus to Speak at 17th Annual Needham Growth Conference investment picks
IP Prototyping Kits Enable Designers to Accelerate Prototyping, Software Development and Integration of IP into SoCs MOUNTAIN VIEW, Calif.
Sign-up for Synopsys Expands IP Accelerated Initiative with New DesignWare IP Prototyping Kits for 10 Interface Protocols investment picks
Success Drives Panasonic SoC Adoption of IC Compiler II MOUNTAIN VIEW, Calif.
Sign-up for Synopsys IC Compiler II Delivers Five Fold Implementation Speed up, Enables Silicon Success investment picks
Q4 2014 Financial Highlights - Revenue: $539.0 million - GAAP earnings per share: $0.39 - Non-GAAP earnings per share: $0.64 FY 2014 Financial Highlights - Revenue: $2.057 billion - GAAP earnings per share: $1.64 - Non-GAAP earnings per share: $2.53 - Cash flow from operations: $551 million - Ending cash balance: $985.8 million MOUNTAIN VIEW, Calif.
Sign-up for Synopsys Posts Financial Results for Fourth Quarter and Fiscal Year 2014 investment picks
Synopsys Inc. (SNPS) on Wednesday reported a fiscal fourth-quarter profit of $62.5 million, or 39 cents a share, on revenue of $539 million.
Sign-up for Synopsys reports earnings rise of almost 10% investment picks
HAPS FPGA-based Prototyping Systems Help More Than 400 Companies Accelerate Time to First Prototype and Avoid Costly Device Re-Spins MOUNTAIN VIEW, Calif.
Sign-up for Synopsys Ships Over 5000 HAPS Prototyping Systems for Software Development, HW/SW Integration and System Validation investment picks
MOUNTAIN VIEW, Calif.
Sign-up for Synopsys Surpasses Milestone of 100 VC Apps on the Verdi Debug Solution investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Synergy Pharmaceuticals Reports Third Quarter 2014 Financial Results to Synopsys Surpasses Milestone of 100 VC Apps on the Verdi Debug Solution
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent